P3.15-29 Defining the Symptom Burden of Non-Small Cell Lung Cancer

Abstract

every 2 weeks to date at our centre. Evidence of PD-L1 expression was not present in either of the patients. All were within the ECOG performance status 2, and none of them were on systemic corticosteroids or immunosuppressive therapy. First case: a 48-year old male, adenocarcinoma lung with brain metastases, TTF-1 positive and EGFR negative, was treated initially with craniotomy followed by whole brain irradiation. 4 cycles of pemetrexed/carboplatin followed by 6 cycles of maintenance pemetrexed were given but the disease progressed. Then he completed 4 cycles of docetaxel which again resulted with progressive disease (PD). Now he is on nivolumab, 6 cycles completed to date. Second case: A 62-year old female, adenocarcinoma lung with contralateral lung metastases, EGFR and ALK negative, was treated initially with concurrent chemoradiation with 3 cycles of pemetrexed/cisplatin. As the disease progressed, 4 cycles of docetaxel/carboplatin were given which again showed PD. Now he is on nivolumab, cycle-6 completed to date. Third case: A 75-year old male, squamous cell esophageal cancer at lower 3 rd , was non-surgical and non-chemo candidate because of uncontrolled diabetes and significant cardiac comorbidity. Nivolumab was started, and received 2 cycles. Result: In the first and second cases,